The size of the endoscope reprocessing market at around $1,880 million in 2021, which is expected to reach about $4,358 million by 2030, advancing at a growth rate of about 10% in the years to come. This is due to the rising inclination toward MIS procedures, the propagating risk of numerous infections related to soiled endoscopes, and the surging strict government regulations spanning all around the globe to control these infections.
The high-level disinfectants and test strips have approximately 35% of the market share in the endoscope reprocessing market in 2021, because of the rising occurrence of numerous endogenous infections like pneumonia and, bacteremia after the usage of endoscopy processes. Similarly, the acceptance of test strips is also growing for the effective measurement of MEC required for high-level decontamination, thus providing faster disinfection reaction time.
Endoscope reprocessing is mainly used in flexible endoscopes, having a higher revenue share of approximately 65% in 2021 in the endoscope reprocessing market. This is since prominent companies are launching AERs that are highly compatible with supple endoscopes. For example, around 90% of corporations are evolving AERs for flexible endoscopes, because of their viability to control and lightweight.
Users are more inclined toward entering into inclusive contracts with ISOs, with the intention of reducing difficulties and further expenses allied with discrete services provided under agreements with producers of medical apparatus. For example, NovaMed Corporation runs a comprehensive service management program that permits clienteles to combine the company’s services into one contract. The contract delivers a lucrative alternative to OEM contracts, in addition to multi-modality and multi-vendor access. Such instances confirm that the acceptance of inclusive endoscope service contracts is snowballing.
The APAC endoscope reprocessing market will have the highest growth rate, over 10%, because of the surge in the count of endoscopic surgeries and the upgrading in healthcare infra. Additionally, China and Japan collectively had approximately 50% share in 2021. This is because of the high frequency of GI-related cancers in both nations. For example, to a government company, there were approximately 3,00,000 GI-related deaths with cancer in the People’s Republic in the year 2021, which has in excess of 13% of all cancer-related deaths in the nation.
With the increasing number of MIS procedures in the people, there is an increase in the demand for endoscope reprocessing instruments.
